A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.
Phase of Trial: Phase IV
Latest Information Update: 16 May 2017
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Rifampicin; Ritonavir
- Indications HIV infections
- Focus Pharmacokinetics
- 10 May 2017 Status changed from recruiting to completed.
- 03 Feb 2015 New trial record